Press Releases
Calidi is at the forefront of the genetic medicine revolution in cancer and other indications
Read the Latest
Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer
SAN DIEGO, Nov. 18, 2024 (GLOBE NEWSWIRE) — Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”),…
Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock
SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) — Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”),…
Calidi Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common Stock
SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi”…
Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results
Announced FDA Clearance of the Northwestern University IND Application for NeuroNova (CLD-101) Clinical Trial in…
Calidi Biotherapeutics to Present Data Supporting RTNova at Upcoming Scientific Conferences
– RTNova, an innovative systemic antitumor enveloped virotherapy, unlocks new possibilities in cancer therapy –…
Calidi Biotherapeutics Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement
SAN DIEGO, Oct. 23, 2024 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi”…